Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

BACKGROUND: Focal adhesion kinase (FAK) inhibitors have demonstrated anti-tumor activity preclinically and are currently being evaluated in humans. A first-in-human study evaluating the novel FAK inhibitor BI 853520 in a predominantly Caucasian population with advanced or metastatic non-hematologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Yang, James Chih-Hsin, Shitara, Kohei, Naito, Yoichi, Cheng, Ann-Lii, Sarashina, Akiko, Pronk, Linda C., Takeuchi, Yoshito, Lin, Chia-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407737/
https://www.ncbi.nlm.nih.gov/pubmed/30725402
http://dx.doi.org/10.1007/s11523-019-00620-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407737/
https://www.ncbi.nlm.nih.gov/pubmed/30725402
http://dx.doi.org/10.1007/s11523-019-00620-0

Ejemplares similares